The Shotlee Journal
Browse Shotlee articles about GLP-1 Medications.
Showing 9 / 934 GLP-1 Medications articles
What began as a treatment for diabetes has rapidly evolved into a powerful force reshaping consumer behavior and Canada's agri-food economy. GLP-1 drugs are no longer niche medical interventions; they are becoming mainstream, driving significant changes in how Canadians eat and shop.
The rise of GLP-1 medications like Ozempic and Mounjaro has brought significant advancements in weight management and diabetes care. However, as more individuals embrace these therapies, understanding and managing potential side effects becomes crucial for a successful health journey.
The rise of GLP-1 medications for weight loss has brought to light a common side effect: temporary hair thinning. This article delves into why this happens and what you can do about it.
Plus-size model Ashley Graham expresses her disappointment and concern over the increasing popularity of GLP-1 weight loss drugs, viewing it as a setback for body acceptance movements.
A recent study published in JAMA Psychiatry has unveiled promising findings regarding GLP-1 receptor agonists, such as semaglutide, and their potential to address a core symptom of major depressive disorder: a lack of motivation. This article delves into the study's methodology, results, and the broader implications for mental health treatment.
GLP-1 agonists are revolutionizing weight management, but their effects extend far beyond the scale. This article delves into the science, the side effects like 'Ozempic breath,' and how these powerful medications are reshaping consumer habits and personal health journeys.
GLP-1 medications are revolutionizing weight management and diabetes care, but their impact extends far beyond the scale. This article delves into the emerging benefits and potential risks associated with these powerful drugs, offering a comprehensive overview for patients and healthcare providers.
The U.S. Food and Drug Administration (FDA) has announced a significant proposal to restrict the compounding of popular GLP-1 medications, including semaglutide and tirzepatide. This move aims to enhance patient safety and uphold the integrity of approved drug products. Here's a comprehensive look at what this means for individuals managing weight and diabetes.
The rise of GLP-1 medications like Ozempic and Mounjaro has brought about new conversations around their side effects, including the emerging concern of 'Ozempic breath.' This article delves into the causes, implications, and effective management strategies for this common issue.
